Skip to main content

Onkologie und Hämatologie

Krebs ist die zweithäufigste Todesursache in Europa1, mit jährlich über 1,9 Millionen Todesfällen2, und stellt mit jährlich über 4 Millionen2 neuen Fällen eine große und wachsende Belastung für die europäischen Gesundheitssysteme dar.

Accord hat sich zum Ziel gesetzt, den Zugang der PatientInnen zu wichtigen Krebstherapien in ganz Europa zu verbessern. Mit Hilfe unseres umfangreichen Portfolios, das über 30 Chemotherapeutika umfasst, möchte Accord Ressourcen in den nationalen Gesundheitssystemen freisetzen, um die onkologische Versorgung zu unterstützen.

Aufbauend auf unseren generischen Grundlagen und mit dem Ziel, uns von der Konkurrenz abzuheben, wird Accord weiterhin in Forschung und Entwicklung investieren, um eine differenzierte Palette von Arzneimitteln zu entwickeln.

Unsere umfangreiche Onkologie-Pipeline konzentriert sich auf weit verbreitete Tumorarten, darunter Brust- und Prostatakrebs, sowie auf hämatologische und krebsbegleitende Therapien. Über 15 Therapien befinden sich derzeit in der Entwicklung und sollen in den nächsten 5 Jahren auf den Markt kommen.

1.    OECD iLibrary -     Health at a Glance: Europe 2020: State of Health in the EU Cycle: Main causes of mortality. Aufgerufen Oktober 2021.
2.    GCO International Agency of Cancer Research – Cancer Today (2020). Aufgerufen Oktober 2021.

Onkologie und Hämatologie

  • Ein führender Anbieter von Generika, Biosimilars und hochwertigen Arzneimitteln für die Onkologie und Hämatologie
  • Accord bietet über 40 onkologische und onkologiebezogene Behandlungen an und ist damit einer der größten Anbieter von Chemotherapieprodukten in Europa.
 Warum Onkologie und Hämatologie?

Onkologie und Hämatologie sind Fachgebiete der Inneren Medizin, die Diagnose, Behandlung und Prävention von Krebs und Blutkrankheiten mit einem multidisziplinären Ansatz umfassen. Trotz großer Fortschritte bei der Behandlung von Krebs und Blutkrankheiten in den letzten Jahren gibt es noch immer Möglichkeiten zur Verbesserung der Wirksamkeits- und Sicherheitsprofile und zur Verringerung der Nebenwirkungen.

Durch die Anwendung unserer innovativen Denkweise bringen wir neue Therapien auf den Markt, die für PatientInnen in der Onkologie und Hämatologie zu echten Verbesserungen führen können.

 Wie wir die Bedürfnisse der PatientInnen in der Onkologie und Hämatologie erfüllen

Accord bietet 95 % der europäischen Bevölkerung Zugang zu onkologischen Therapien.

Aufbauend auf unserer langjährigen Erfahrung im Bereich der onkologischen Generika führen wir neue Medikamente ein, die einen Mehrwert bieten und den PatientInnen zusätzliche Behandlungsmöglichkeiten eröffnen.

General (the “Site") is owned and operated by Accord Healthcare, Ltd. (“Accord”), a company registered in England and Wales, with company number 04596349 and with registered office at Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom. Accord’s VAT number is GB 894350693.

Terms of Use
By accessing the Site or by otherwise accessing any content found on this Site, you agree to be bound by the following terms and conditions (“T&C”).

Contents of this Site
All the information and contents of the Site (including, but not limited to, its graphics, logos, designs, images and source codes used for programming) are the property of Accord or its licensors, as the case may be.

You may not use or reproduce or allow anyone to use or reproduce any “Accord” names and logos, and any other graphics or trademarks (whether registered or unregistered) appearing on the Site for any reason without written permission from Accord.

The software that operates the Site is proprietary software and you may not use it except as expressly allowed under these T&C. You may not copy, reverse engineer, modify or otherwise deal with the software.

Where the Site contains links to other sites and resources provided by third parties, these links are provided for your information and convenience only. Accord does not have control over, and is not responsible for, the availability and content of those sites and resources. 

Changes to the Site, its contents and these T&C
Accord reserves the right to alter the Site, its contents and these T&C at any time, without prior notice. Any modification will take effect immediately. You agree to check these T&C regularly for modifications and additions.

Contents Use
You may download material displayed on the Site for non-commercial, personal use only, provided you also retain all copyright and other proprietary notices contained in the materials or as specified on the Site. Save as expressly permitted above, all use and reproduction of any material on this Site or any incorporation of the same into any other material, in whatever media or format, is strictly prohibited. You agree not to use the Site for any commercial or business purposes.

Slavery and Human Trafficking
Accord is absolutely committed to preventing slavery and human trafficking in its business activities and ensuring to the best of its ability that its supply chain is free from such activities. For further details, see Accord’s Modern Slavery Act Statement.

Personal Data
Accord may process the personal data supplied by you to Accord in accordance with Accord’s Cookies and Privacy Policy.

Liability and Indemnity
Although Accord endeavours to ensure the high quality and accuracy of the Site, Accord makes no warranty, express or implied, such as to the accuracy, completeness or adequacy, of the contents of the Site, which are provided "as is".

In no event will Accord, its affiliates, agents, suppliers or licensors be liable for any direct, special, incidental, exemplary, punitive, consequential or other loss or damage (including, without limitation, damages for loss of business profits, business interruption, loss of business information or other pecuniary loss) that may arise directly or indirectly from the use of (or failure to use) or reliance on the contents of this Site, even if Accord has been advised of the possibility that such damages may arise. For the avoidance of doubt:

  • Accord does not guarantee absence of virus or other elements that could damage or alter your computer system, electronic documents or files. Accord hereby notifies to all users that these may occur. Therefore, Accord does not accept liability for any damage that these elements could cause to you or to third parties.
  • Accord will not be liable if for any reason the Site is unavailable at any time or for any period. Accord accepts no responsibility for any errors, omissions, delays, or losses including loss of data during or as a result of the unavailability of the Site.

You agree to indemnify Accord, its affiliates, agents, suppliers or licensors immediately on demand, against all claims, liability, damages, costs and expenses, including reasonable legal fees, arising out of any breach of these T&C by you or your use of the Site.

Governing Law and Jurisdiction
These T&C will be governed by and construed in accordance with the laws of England. You (and Accord) submit irrevocably to the exclusive jurisdiction of the English Courts.

Other Terms
Notices to Accord must be given in writing, by letter, and sent to Sage House, 319 Pinner Road, North Harrow Middlesex, HA1 4HF, United Kingdom.

If any provision in these T&C is determined to be illegal, invalid or unenforceable, in whole or in part, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable, be deemed not to form part of these T&C and the legality, validity and enforceability of the remainder of these T&C shall not be affected.

Save as expressly referred to therein, Accord makes no representations or warranties of any kind, express or implied, with respect to Site and its contents.

Headings in these T&C are for convenience only and have no legal meaning or effect, nor shall they be taken into account in interpreting these T&C.

Accord rights under the T&C may be waived only in writing and specifically.

The board of directors and management teams of Accord Healthcare Ltd’s (AHL) and its subsidiaries are fully committed to complying with competition law. The fundamental objective of competition law is to prevent distortion of competition in the market because competition ensures an efficient allocation of resources and, ultimately, enhances consumer welfare.

AHL is committed to bringing affordable life-saving medicines to patients and has thus adopted a robust compliance programme that includes a fair competition policy, employee training to aid understanding of competition law and how it applies to our business, and a whistleblowing line allowing our employees and business partners to safely (and anonymously) report any policy breaches.


Accord Healthcare Ltd Board of Directors
October 2019